In this phase Ib trial online now NatureMedicine Ryan Sullivan and colleagues show treatment with BRAFMEK inhibitors followed by antiPDL1 in BRAFmutant melanoma patients is safe and shows promising antitumor activity httpbit.ly2I7uXj4Â canc
In this phase Ib trial online now @NatureMedicine, Ryan Sullivan and colleagues show treatment with BRAF/MEK inhibitors followed by anti-PD-L1 in BRAF-mutant #melanoma patients is safe and shows promising anti-tumor activity http://bit.ly/2I7uXj4 #canc
More From BioPortfolio on "In this phase Ib trial online now @NatureMedicine, Ryan Sullivan and colleagues show treatment with BRAF/MEK inhibitors followed by anti-PD-L1 in BRAF-mutant #melanoma patients is safe and shows promising anti-tumor activity http://bit.ly/2I7uXj4 #canc"